Entera Bio Ltd. (ENTX) Stock Price & Analysis
Entera Bio Ltd. (ENTX) — MoonshotScore 58/100 (Fair band), calculated Nov 22, 2026. Price $3.31 (+0.76%), as of the Nov 20, 2026 trading session; market cap $576M.
Educational signal · not a buy or sell recommendation · How to read this
Entera Bio Ltd. · ENTX · NASDAQ
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered large molecule therapeutics. Their lead product candidates target unmet medical needs in hypoparathyroidism, osteoporosis, and non-union fractures.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Entera Bio (ENTX)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Strong price action running well ahead of the business — stalling growth underneath; a move to treat with suspicion, not chase. Business Quality: Average; Financial Safety: Sound; Valuation: Fair; Growth Durability: Shrinking; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- ROE -20.3% · ROA -7.8%
Holding back: soft growth
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 61 | Fair | |
| 61 | Fair | |
| 61 | Fair | |
| 57 | Fair | |
| 57 | Fair | |
| 57 | Fair |
The score moved from 57 in the stored Nov 21, 2026 snapshot to 58 in the current publication computed Nov 22, 2026 (+1); the largest pillar moves were Momentum +3 and Valuation -2. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $3.31 | |
| Change on the day | +0.76% | |
| Market capitalisation | $576M | — |
| Price / earnings (trailing) | 267.29 | |
| Shares traded on the day | 468.4K |
Price & events
Other perspectives
Council score for Entera Bio (ENTX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 22, 2026, except a card that shows its own read date.
What is Entera Bio (ENTX), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Entera Bio Ltd. (ENTX) is listed on NASDAQ. It employs 27 people. The market values it at $576M.
What do the latest results show for Entera Bio (ENTX)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
What are the financial strengths and risks for Entera Bio (ENTX)?
Short answer · as of
The MoonshotScore pillars rate balance-sheet strength, positive momentum as strengths. What is holding it back is soft growth. The distress and quality screens read Piotroski F 3. Trailing ratios: ROE -20.3% · ROA -7.8%.
Data-derived red flags
- Negative return on equity (-20.3%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Entera Bio (ENTX)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $54.58M · EPS -0.50 · 3 analysts. The stored analyst-target capture is expired, so a current target watchpoint is unavailable.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for ENTX.
Checked against the records this page reads, on the dates shown above.
How does Entera Bio compare with its peers?
Short answer
Entera Bio's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $12.85 Nov 20, 2026 | $1.40B | 97 5-pillar Nov 22, 2026 | |
| $18.41 Nov 20, 2026 | $1.31B | 96 5-pillar Nov 22, 2026 | |
| $13.09 Nov 20, 2026 | $462M | 92 5-pillar Nov 22, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 22, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 22, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 87 5-pillar Nov 22, 2026 | |
| $46.63 Nov 20, 2026 | $1.39B | 77 5-pillar Nov 22, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 22, 2026 | |
| $19.19 Nov 20, 2026 | $1.18B | 69 5-pillar Nov 22, 2026 | |
| $38.85 Nov 20, 2026 | $1.26B | 69 5-pillar Nov 22, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 22, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 64 5-pillar Nov 22, 2026 | |
| Entera Bio (ENTX) — this page | $3.31 | $576M | 58 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
- $9.00 – $9.00
- Last captured analyst target (expired, captured Nov 18, 2026)
- $9.00
- Last captured median analyst target (expired, captured Nov 18, 2026)
- $9.00
- Revenue estimate
- $54.58M
- EPS estimate
- $-0.50
Historical target record · Captured · Capture expired; not a current watchpoint.
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 7, 2026
- Transactions
- 14
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 0
- Other transactions
- 14
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ENTX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ENTX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Entera Bio (ENTX)?
What Investors Ask About Entera Bio (ENTX)
These answers are editorial: 1 of these 9 answers is drawn from the ENTX research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ENTX?
ENTX carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered large molecule therapeutics.
Is ENTX a good stock to buy?
Stock Expert AI does not rate ENTX buy, sell or hold. Entera Bio Ltd. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ENTX stock price today?
The last price recorded for Entera Bio Ltd. (ENTX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ENTX price target?
The last analyst consensus price target we captured for Entera Bio Ltd. (ENTX), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.
What are the main risks for ENTX?
The main risks for Entera Bio Ltd. revolve around the inherent uncertainties of clinical-stage drug development. These include the potential for unfavorable clinical trial results, failure to obtain regulatory approval from the FDA or other health authorities, and competition from established pharmaceutical companies with greater resources.
What are the key factors to evaluate for ENTX?
Entera Bio Ltd. (ENTX) holds a MoonshotScore in the moderate range. To weigh it, start with the trailing P/E under Price & valuation on this page. Collaboration with Amgen Inc. provides validation of Entera Bio's technology and potential for future partnerships. Not financial advice.
How frequently does ENTX data refresh on this page?
ENTX's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ENTX's recent stock price performance?
Entera Bio Ltd. (ENTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary oral drug delivery technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ENTX overvalued or undervalued right now?
The trailing P/E of Entera Bio Ltd. (ENTX) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 19 figures on this page — 12 from Financial Modeling Prep (FMP), 5 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com